These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 15267190)

  • 41. A randomised controlled trial assessing the effect of adding clarithromycin to rifampicin, ofloxacin and minocycline in the treatment of single lesion paucibacillary leprosy in Agra District, India.
    Girdhar A; Kumar A; Girdhar BK
    Lepr Rev; 2011 Mar; 82(1):46-54. PubMed ID: 21644471
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Evaluation years in leprosy patients treated with single dose alternative scheme ROM (rifampin, ofloxacin, minocycline), after seven to nine].
    Diniz LM; Catabriga MD; Souza Filho JB
    Rev Soc Bras Med Trop; 2010; 43(6):695-9. PubMed ID: 21181026
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Therapeutic prospects for paucibacillary leprosy.
    Katoch K
    Indian J Lepr; 2000; 72(3):351-61. PubMed ID: 11105276
    [No Abstract]   [Full Text] [Related]  

  • 44. A study on trend of relapse in leprosy and factors influencing relapse.
    Ali MK; Thorat DM; Subramanian M; Parthasarathy G; Selvaraj U; Prabhakar V
    Indian J Lepr; 2005; 77(2):105-15. PubMed ID: 16044808
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinico-histopathological study of multidrug therapy in indeterminate leprosy.
    Kar PK; Jha PK; Panaych JS; Snehi PS
    Indian J Lepr; 1990; 62(1):98-103. PubMed ID: 2358708
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Field trials of a single dose of the combination rifampicin-ofloxacin-minocycline (ROM) for the treatment of paucibacillary leprosy.
    Gupte MD
    Lepr Rev; 2000 Dec; 71 Suppl():S77-80. PubMed ID: 11201893
    [No Abstract]   [Full Text] [Related]  

  • 47. World Health Organization (WHO) antibiotic regimen against other regimens for the treatment of leprosy: a systematic review and meta-analysis.
    Lazo-Porras M; Prutsky GJ; Barrionuevo P; Tapia JC; Ugarte-Gil C; Ponce OJ; Acuña-Villaorduña A; Domecq JP; De la Cruz-Luque C; Prokop LJ; Málaga G
    BMC Infect Dis; 2020 Jan; 20(1):62. PubMed ID: 31959113
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effectiveness of multidrug therapy in multibacillary leprosy: a long-term follow-up of 34 multibacillary leprosy patients treated with multidrug regimens till skin smear negativity.
    Shaw IN; Christian M; Jesudasan K; Kurian N; Rao GS
    Lepr Rev; 2003 Jun; 74(2):141-7. PubMed ID: 12862255
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Changes in the size and number of skin lesions in PB leprosy on treatment and follow-up.
    Rao PN; Suneetha S; Pratap DV
    Lepr Rev; 2011 Sep; 82(3):244-52. PubMed ID: 22125932
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Elimination of leprosy in the federated states of micronesia by intensive case finding, treatment with WHO/MDT and administration of chemoprophylaxis.
    Diletto C
    Int J Lepr Other Mycobact Dis; 1999 Dec; 67(4 Suppl):S10-3. PubMed ID: 10700929
    [No Abstract]   [Full Text] [Related]  

  • 51. Histological resolution and bacterial clearance with pulse ROM therapy in borderline lepromatous leprosy.
    Suneetha S; Reddy R
    Int J Lepr Other Mycobact Dis; 2001 Mar; 69(1):53-4. PubMed ID: 11480321
    [No Abstract]   [Full Text] [Related]  

  • 52. Relapse of multibacillary leprosy after treatment with daily rifampin plus ofloxacin for four weeks.
    Ji B
    Int J Lepr Other Mycobact Dis; 1998 Sep; 66(3):391-2. PubMed ID: 9934368
    [No Abstract]   [Full Text] [Related]  

  • 53. Prospective study on the relationship between intensive bactericidal therapy and leprosy reactions.
    Groenen G; Janssens L; Kayembe T; Nollet E; Coussens L; Pattyn SR
    Int J Lepr Other Mycobact Dis; 1986 Jun; 54(2):236-44. PubMed ID: 3722962
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Combined 12-month WHO/MDT MB regimen and Mycobacterium w. vaccine in multibacillary leprosy: a follow-up of 136 patients.
    Kaur I; Dogra S; Kumar B; Radotra BD
    Int J Lepr Other Mycobact Dis; 2002 Sep; 70(3):174-81. PubMed ID: 12483965
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Developing new MDT regimens for MB patients; time to test ROM 12 month regimens globally.
    Lockwood DN; Cunha Mda G
    Lepr Rev; 2012 Sep; 83(3):241-4. PubMed ID: 23356024
    [No Abstract]   [Full Text] [Related]  

  • 56. Granuloma annulare treated with rifampin, ofloxacin, and minocycline combination therapy.
    Marcus DV; Mahmoud BH; Hamzavi IH
    Arch Dermatol; 2009 Jul; 145(7):787-9. PubMed ID: 19620560
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A retrospective study of the effect of modified multi-drug therapy in Nepali leprosy patients following the development of adverse effects due to dapsone.
    Sapkota BR; Shrestha K; Pandey B; Walker SL
    Lepr Rev; 2008 Dec; 79(4):425-8. PubMed ID: 19274989
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of treatment on PCR positivity in multibacillary leprosy patients treated with conventional and newer drugs ofloxacin and minocycline.
    Singh HB; Katoch K; Natrajan M; Sharma RK; Gupta UD; Sharma VD; Singh D; Chauhan DS; Srivastava K; Katoch VM
    Acta Leprol; 1999; 11(4):179-82. PubMed ID: 10987049
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Analysis of gene probes and gene amplification techniques for diagnosis and monitoring of treatment in childhood leprosy.
    Kamal R; Dayal R; Katoch VM; Katoch K
    Lepr Rev; 2006 Jun; 77(2):141-6. PubMed ID: 16895070
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Newer drugs in leprosy.
    Grosset JH
    Int J Lepr Other Mycobact Dis; 2001 Jun; 69(2 Suppl):S14-8. PubMed ID: 11757174
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.